DEF 14A: Danaher Corp. Files Proxy Statement for 2024 Annual Meeting, Outlines Executive Compensation and Governance

Danaher Corporation's proxy statement details proposals for the 2024 annual meeting, including director elections, executive compensation, and shareholder proposals.

Summary

• Danaher Corporation has filed its proxy statement for the 2024 Annual Meeting of Shareholders.
• The meeting will include voting on the election of thirteen directors, ratification of the independent accounting firm, an advisory vote on executive compensation, and two shareholder proposals.
• In 2023, Danaher spun off its Veralto business and acquired Abcam plc for approximately $5.6 billion.
• The company invested approximately $1.5 billion in research and development and $1.4 billion in capital expenditures.
• Danaher returned approximately $778 million to common shareholders through cash dividends.
• The company generated $23.9 billion in sales, $5.2 billion in operating profit and $6.5 billion in operating cash flow.
• Danaher's annualized total shareholder return (TSR) ranks fourth out of 220 S&P 500 companies publicly traded since 1985.
• The proxy statement includes details on corporate governance, director compensation, and executive compensation.
• Shareholders are asked to vote on a proposal to reduce the percentage of shares required to call a special meeting from 25% to 15% and a proposal requesting a report on the effectiveness of the Company's diversity, equity, and inclusion efforts.
• The Board of Directors recommends voting for the election of directors and ratification of the accounting firm, and against the shareholder proposals.

Sentiment

Score: 7

Explanation: The document presents a balanced view of Danaher's performance, highlighting both achievements and areas for improvement. The overall tone is positive, reflecting the company's strong financial results and strategic initiatives.

Positives

• Danaher's annualized total shareholder return (TSR) ranks fourth out of 220 S&P 500 companies publicly traded since 1985.
• The company invested approximately $1.5 billion in research and development and $1.4 billion in capital expenditures.
• Danaher returned approximately $778 million to common shareholders through cash dividends.
• The company generated $23.9 billion in sales, $5.2 billion in operating profit and $6.5 billion in operating cash flow.
• More than half of the Company's director nominees for the 2024 annual meeting are diverse from a gender and/or race/ethnicity perspective.
• The 2023 CPA-Zicklin Index of Corporate Political Disclosure and Accountability ranked Danaher as a First Tier company.

Negatives

• A shareholder proposal requests a report on the effectiveness of the Company's diversity, equity, and inclusion efforts, suggesting potential areas for improvement.
• Danaher stock has gone downhill since its $290 price in December 2021.

Risks

• The proxy statement mentions risks related to cybersecurity, indicating a potential vulnerability.
• The company faces risks associated with strategic acquisitions and integrations.
• The company faces risks associated with economic cycles and competition.

Future Outlook

The company aims to sustainably expand its business in high-growth geographies and market segments, identify, consummate and integrate appropriate acquisitions, develop innovative and differentiated new products and services, adjust to rapidly changing technologies, business cycles and competition and address the demands of an increasingly regulated environment.

Industry Context

The document mentions that the science and technology markets in which Danaher operates are competitive, with demand sometimes exceeding the supply of talent, resulting in significant increases in compensation paid by the companies with whom it competes for this talent.

Comparison to Industry Standards

• Danaher's annualized total shareholder return (TSR) ranks fourth out of 220 S&P 500 companies publicly traded since 1985.
• Danaher is the only company in its peer group whose TSR outperformed the S&P 500 Index by more than 1,600 basis points over every rolling 5-year period from and including 1999-2023.
• The document references a peer group of companies including 3M Company, Boston Scientific Corporation, IQVIA Holdings Inc., Abbott Laboratories, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Ecolab Inc., Medtronic Inc., Amgen Inc., Eli Lilly and Company, Stryker Corporation, Baxter International, Inc., Honeywell International Inc., Thermo Fisher Scientific Inc., and Becton Dickinson & Co.
• The document references a peer group of companies including Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Medtronic Inc., Agilent Technologies, Eli Lilly and Company, Merck & Co., Amgen Inc., Gilead Sciences, Stryker Corporation, Becton Dickinson & Co., IQVIA Holdings Inc., Thermo Fisher Scientific Inc.

Corporate Governance

Legal Proceedings

• The document mentions that the Company was sued by a pension fund for its lack of diverse leadership.

Related Party Transactions

• Steven and Mitchell Rales receive certain benefits and services from Danaher, including tax and accounting services, office space, and a personal car.
• FJ 900, Inc., an indirect, wholly-owned subsidiary of Danaher, has airplane management agreements with entities controlled by Mitchell and Steven Rales.
• Danaher licensed, at fair market value, a suite from the Washington Commanders for the 2023-2024 NFL football season for approximately $560,000. Mitchell Rales is a greater-than-10% owner of the Washington Commanders.
• Following the Veralto Spin-Off, Danaher and Veralto entered into various agreements to effect the transaction and provide a framework for their relationship after the transaction.

Stakeholder Impact

• The proxy statement outlines proposals that directly impact shareholders, including director elections and executive compensation.
• The company's sustainability efforts and DE+I initiatives have implications for employees and the broader community.
• The company's financial performance and strategic decisions affect customers, suppliers, and creditors.

Next Steps

• Shareholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Shareholders on May 7, 2024.

Key Dates

Keywords

proxy statement, annual meeting, executive compensation, corporate governance, director election, shareholder proposal, sustainability, diversity, equity, inclusion, financial performance, Veralto, Abcam, TSR, Ernst & Young